The role of АВС transporters in drug resistance to bortezomib in multiple myeloma (original) (raw)

Immunogenetic and Pharmacochemical Characterization of the Abo System Glycoprotein Properties as Criteria of Individual Sensitivity to Antitumor Agent Bortezomib in the Plasma Cell Myeloma Patients

T. Liubarets

Проблеми радіаційної медицини та радіобіології = Problems of Radiation Medicine and Radiobiology, 2019

View PDFchevron_right

Proteasome inhibitors: A rational for clinical use in the treatment of multiple myeloma

Svetislav Vrbic

Racionalna terapija

View PDFchevron_right

Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells

Remy Schlossberg

Leukemia research, 2019

View PDFchevron_right

[Successful use of vemurafenib in a patient with resistant hairy cell leukemia]

Любовь Аль-Ради, Andrey Sudarikov, A. Kovrigina, Larisa Kuzmina

Terapevticheskiĭ arkhiv, 2013

View PDFchevron_right

Current approaches to supportive care in multiple myeloma

Nenad Govedarovic

Srpski arhiv za celokupno lekarstvo, 2011

View PDFchevron_right

Induction therapy and the role of stem cell transplantation in the treatment of myeloma multiplex in patients aged below 65 years

Bela Balint

Srpski arhiv za celokupno lekarstvo, 2011

View PDFchevron_right

[New concept of the treatment in elderly patients with multiple myeloma]

Jelena Bila, Mirjana Gotic

Srpski arhiv za celokupno lekarstvo, 2011

View PDFchevron_right

Complex Analysis of the Role of Cytokine Gene Polymorphisms as Prognostic Factor of the Risk of Plasma Cell Myeloma in Persons Suffered After the Chornobyl NPP Accident

T. Liubarets

Проблеми радіаційної медицини та радіобіології = Problems of Radiation Medicine and Radiobiology

View PDFchevron_right

Ionizing Radiation and Cytokines: The Role in the Pathogenesis of Plasma Cell Myeloma (Literature Review)

T. Liubarets

Проблеми радіаційної медицини та радіобіології = Problems of Radiation Medicine and Radiobiology

View PDFchevron_right

Molecular Genetic Structure of Multiple Myeloma Tumour Cells Prior to Treatment and at the Time of Relapse: Short Review and Case Report

Anna Sergeeva

Russian journal of hematology and transfusiology, 2019

View PDFchevron_right

The Content of Active AKT1 Antiapoptotic Protein in Bone Marrow Cell Lyzate in Primary Myelodysplastic Syndromes

Olga Krasko

2014

View PDFchevron_right

News in the studies of multidrug resistance of breast cancer cells

Gelena Guens

Advances in molecular oncology, 2015

View PDFchevron_right

ABCA1-mediated mechanism of resistance to amphotericin B toxicity in mammalian cells

Shabaan Sayed

FEBS Open Bio, 2019

View PDFchevron_right

Recognition of the Sodium-Dependent Phosphate Transporter NaPi2b by Monoclonal Antibodies N-NaPi2b in Ovarian Cancer Cells

Natalia Akberova

Uchenye Zapiski Kazanskogo Universiteta. Seriya Estestvennye Nauki, 2020

View PDFchevron_right

The systemic factors of mitigating the contribution of the reversible phenotypic transitions of malignant cells to therapeutic resistance

Алексей Георгиевич Голубев

Voprosy Onkologii

View PDFchevron_right

Loading rate of exogenous and autoantigenic determinants on major histocompatibility complex class ii mediates resistance to multiple sclerosis

Ivan Kiselev

Доклады Академии наук, 2019

View PDFchevron_right

Autologous hematopoietic stem cell transplantation in multiple myeloma and lymphoma: an analysis of factors influencing stem cell collection and hematological …

Łucja Kachel

Medical Oncology, 2011

View PDFchevron_right

Vemurafenib resistant melanoma cells acquire mesenchymal stem cell-like properties

Yegor E Yegorov

Advances in molecular oncology

View PDFchevron_right

Системные факторы противодействия вкладу обратимых переходов злокачественных клеток между фенотипическими состояниями в резистентность к терапии

Alexey Golubev

Problems in oncology

View PDFchevron_right

Mechanisms of Sensitivity of Soft Tissue Sarcoma Cells to Temozolomide

Ramil Khusnutdinov

View PDFchevron_right

Frequency of coexistence and kinetics of the BCR-ABL1 transcript level and allele burden of JAK2V617F and CALR Type 1, 2 gene mutations in patients with chronic myeloid leukemia

T. Makarik

Russian journal of hematology and transfusiology, 2020

View PDFchevron_right

Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Single-Center Real Life Experience

Chiara Cantò

Blood, 2018

View PDFchevron_right

ДНК-абзимы при аутоиммунной патологии в клинике и эксперименте

Sergey Suchkov

Научно-практическая ревматология, 2003

View PDFchevron_right

Dasatinib in First- and Second-Line Therapy of Chronic Myeloid Leukemia: Efficacy, Safety and Quality of Life

Elza Lomaia

Clinical oncohematology, 2017

View PDFchevron_right

GFI1b As a Novel Oncosuppressor in AML

Nasiru Aliyu

Blood, 2016

View PDFchevron_right

The concurrence of light-chain deposition disease, AL-amyloidosis, and cast nephropathy in a patient with multiple myeloma

Helena V Zakharova

Terapevticheskii Arkhiv, 2015

View PDFchevron_right

Late myelotoxicity of high-dose chemotherapy according to the modified NHL-BFM-90 program in adult patients with diffuse large B-cell lymphoma

Sergei Kulikov

Terapevticheskii arkhiv, 2016

View PDFchevron_right

АВ0-INCOMPATIBILITY in Allogeneic Hematopoietic Stem Cell Transplantation: 15-YEARS Experience of R.M. Gorbacheva Memorial Research Institute for Children Oncology, Hematology and Transplantation

L. Zubarovskaya

Oncohematology, 2016

View PDFchevron_right

Glioblastoma: a molecular genetic portrait and modern therapeutic strategies for drug treatment

Gelena Guens

Advances in Molecular Oncology, 2021

View PDFchevron_right

Glioblastoma Multiforme: Pathogenesis and Molecular Markers

Oleg Kit

Problems in oncology, 2017

View PDFchevron_right

Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndromes and Clinical Significance of WT1 Gene Overexpression

Nikolay Mamaev

Clinical Oncohematology, 2014

View PDFchevron_right

Everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab: a prospective multicenter study CRAD001LRU02T

Ashok Panneerselvam

Targeted Oncology, 2014

View PDFchevron_right

Efficiency of Bone Marrow Precursor Cell Colony-Forming as a Predictor of Disease Course in Plasma Cell Myeloma Patients with a History of Radiation Exposure

T. Liubarets

Problemy radiatsiinoi medytsyny ta radiobiolohii, 2020

View PDFchevron_right

MTR-14CELL Intrinsic Circadaian Regulation of Temozolomide Cytotoxicity in a Glioblastoma Model

jackson karanja

Neuro-Oncology, 2015

View PDFchevron_right

[Updated criteria for diagnosis and risk stratification in patients with multiple myeloma]

Jelena Bila

Srpski arhiv za celokupno lekarstvo, 2011

View PDFchevron_right